Fig. 4.

Loss of anti-RBD FcγR-binding antibodies and ADCP responses to VOC RBDs in BNT162b2 and convalescent plasma. A FcγRIIa-H131 and B FcγRIIIa-V158 binding levels of RBD-specific antibodies using plasma of BNT162b2 (2 weeks following second dose; blue; n = 16) and mild/moderate convalescent COVID-19 patients (green; median 38 days post symptom onset; n = 15) as measured via multiplexing. C Fold change of anti-RBD FcγRIIa-H131 binding levels to RBD variants in comparison to ancestral RBD of BNT162b2 plasma. D Fold change of FcγRIIIa-V158 levels of RBD variants in comparison to ancestral of BNT162b2 plasma. Reciprocal ED₅₀ values were calculated using the normalized FcγR binding MFI value for an 8-point serial plasma titration. Fold change was calculated as follows: (geometric mean of reciprocal ED₅₀ or ID₅₀, respectively ancestral RBD) divided by (geometric mean reciprocal ED₅₀ or ID₅₀, respectively variant RBD). Friedman’s non-parametric test with Dunn’s multiple comparisons was used to assess statistical significance. E FcγRIIa-H131binding (Reciprocal ED₅₀) and F FcγRIIIa-V158 inhibition levels to RBD of Omicron variant with fold change of BNT162b2 plasma indicated above in blue. Mann–Whitney U-test used to assess statistical significance. G, H Spearman correlations of phagocytosis activity (reciprocal ED₅₀) using THP-1 monocytes and multiplex FcRIIa-H131 data (reciprocal ED₅₀) against the ancestral and Beta RBD. I ADCP by THP-1 monocytes induced by the plasma of BNT162b2 against the ancestral and Beta RBD shown as phagocytic score ED₅₀. Wilcoxon matched pairs signed rank test was used to assess statistical significance. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****)